107.50Open107.50Pre Close0 Volume0 Open Interest400.00Strike Price0.00Turnover91.27%IV-15.58%PremiumDec 20, 2024Expiry Date146.93Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9928Delta0.0013Gamma1.72Leverage Ratio-0.0140Theta-0.0278Rho-1.71Eff Leverage0.0104Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet